This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
J

ASCO® 2024 Insights: "LIBRETTO-432 Trial - Adjuvant Selpercatinib vs. Placebo in Stage IB-IIIA RET+ NSCLC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Jonathan Goldman
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Jonathan Goldman
143 views
June 14, 2024

Chapters

Introduction to RET & Selpercatinib

00:00

LIBRETTO-001 Trial & Results

01:59

Adverse Events & Management

04:03

Phase III Trial & Efficacy

06:02

LIBRETTO-432 Trial Design & Goals

07:55

0 Comments
Login to view comments. Click here to Login

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

2024 ASCO® Annual Meeting Insights Hub: Lung Videos

17:22
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "SCLC Treatment Evolution - Debunking Myths…

Feat. A. Chiang
40:00
ecancer

ASCO® 2024: Highlights and Analysis of Key Solid Cancer Trials

Feat. B. Gyawali
04:26
ecancer

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance vs. Local C…

Feat. P. Iyengar
View All

Related Content

AUTOPLAY
17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
36:14
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

Feat. B. Halmos
29:25
Northwestern Medicine Oncology and Hematology

Hyperprogression in Cancer Treated With Immunotherapy

Feat. Y. Chae
11:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…

Feat. J. West
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
19:33
ecancer

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

Feat. E. Felip, A. Spira, A. Passaro, A. Addeo
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
09:40
John Conibear

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

09:37
Luis Raez

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

07:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Cli…

Feat. J. West
22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
08:18
MI&T Congressi

ADC in Combination With Immunotherapy for NSCLC

Feat. S. Liu
20:27
Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst
22:08
Integrity CE

How the Experts Treat: Early Stage NSCLC With Curative Intent

Feat. S. Liu
11:40
MI&T Congressi

New Immune Checkpoint Inhibitors in Lung Cancer

Feat. S. Peters
26:42
Total Health

ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 AS…

Feat. J. Bauman
23:36
CHEST 2022 Coverage

Immune Checkpoint Inhibitor Pneumonitis in Lung Cancer

Feat. J. Possick
17:57
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Expert Discussion on New Treatment Options…

Feat. D. Carbone, B. Stiles
20:43
GRACE

Newer Types of Treatment for Lung Cancer: ADCs and Bispecifics

Feat. L. Bazhenova